Biomaterial Database

Contribution of activated C3 to lymphocyte-mediated target lysis: complement-dependent cellular cytotoxicity. 1984

E Yefenof, and E Klein, and I Yron

Lysis of Raji cells by human lymphocytes was found to be enhanced if human serum was added to the assay. This was not due to the contribution of antibodies because hypogammaglobulinemic serum also augmented cytotoxicity. The results suggest that the mechanism of the enhancement was due to activation of C3 by the Raji cells. We assume that the cleavage products are deposited on cell surfaces in such a way that they contribute to contact between effector and target. Previous reports in two antibody-dependent cellular cytotoxicity systems provided other examples for the existence of this phenomenon.

UI	MeSH Term	Description	Entries
D007370	Interferon Type I	Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).	Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008214	Lymphocytes	White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.	Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D001769	Blood	The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D002051	Burkitt Lymphoma	A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.	African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002460	Cell Line	Established cell cultures that have the potential to propagate indefinitely.	Cell Lines,Line, Cell,Lines, Cell
D003167	Complement Activation	The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES.	Activation, Complement,Activations, Complement,Complement Activations
D003176	Complement C3	A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.	C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003602	Cytotoxicity, Immunologic	The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement.	Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

E Yefenof, and E Klein, and I Yron

Complement (C3) receptor-bearing lymphocyte-mediated cytotoxicity and lymphotoxin responses.

November 1975, Cellular immunology,

E Yefenof, and E Klein, and I Yron

The cellular target for lymphocyte-mediated cytotoxicity.

December 1975, The Keio journal of medicine,

E Yefenof, and E Klein, and I Yron

Variance in resistance to natural and antibody-dependent cellular cytotoxicity and to complement-mediated lysis among K562 lines.

August 1983, International journal of cancer,

E Yefenof, and E Klein, and I Yron

The use of a hapten-Fab conjugate to sensitize target cells for antibody-dependent complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity.

February 1991, Journal of immunological methods,

E Yefenof, and E Klein, and I Yron

[The action of pronase on the recognition and lysis of target cells in natural cellular mediated cytotoxicity and antibody-dependent cellular cytotoxicity].

January 1984, Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Bacteriologia, virusologia, parazitologia, epidemiologia,

E Yefenof, and E Klein, and I Yron

Complement-mediated factors in cellular lysis.

May 1979, New York state journal of medicine,

E Yefenof, and E Klein, and I Yron

Merkel cell carcinoma and cellular cytotoxicity: sensitivity to cellular lysis and screening for potential target antigens suitable for antibody-dependent cellular cytotoxicity.

August 2018, Cancer immunology, immunotherapy : CII,

E Yefenof, and E Klein, and I Yron

Rat eosinophil-mediated antibody-dependent cellular cytotoxicity: investigations of the mechanisms of target cell lysis and inhibition by glucocorticoids.

June 1982, Clinical and experimental immunology,

E Yefenof, and E Klein, and I Yron

Human T lymphocyte differentiation antigens as target for immunotoxins or complement-mediated cytotoxicity.

August 1988, Scandinavian journal of immunology,